three years of Apotheke threads, summarised so you do not have to read them
three years of Apotheke threads, summarised so you do not have to read them, which sounds obvious until you try to state the evidence for it. Marketing authorisation is granted centrally for these products; reimbursement, pricing and prescribing criteria are national competences. Those are decided by different bodies…
Not convinced — cross-border prescription recognition is narrower than you are describing and the exceptions matter.
That shortage notice was national and does not apply where the question is coming from.
the EMA authorises, member states decide who pays
Same. Naming the country in the first line would fix most of the bad advice on this board.
That is an authorisation question and you have answered a reimbursement one. They are decided by different bodies.
keep the prescription and the receipt, both matter for claims
Yes. Pack sizes differ enough that per-month price comparisons across borders need to be normalised before they mean anything.
Published reimbursement criteria exist in most member states and are usually available in the national language. They are the authoritative answer to eligibility questions that this board can only guess at.
Small fix — those two prices are for different pack sizes, which accounts for most of the gap.
Small fix — those two prices are for different pack sizes, which accounts for most of the gap.
This is the split the whole board depends on. Authorisation is European; payment is national.
Read the published reimbursement criteria where I live rather than asking. Took twenty minutes and answered everything.
the reimbursement criteria are published in most member states